AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 82 min read$BMY

BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial

Bristol Myers Squibb's (BMS) Zenbexus (iberdomide) met its primary endpoint in a Phase III trial, doubling progression-free survival (PFS) in multiple myeloma patients. The trial showed a median PFS of 42 months for Zenbexus compared to 20 months for standard therapy. The FDA approved Zenbexus for relapsed/refractory multiple myeloma in August 2026. BMS plans to present full results at the American Society of Hematology meeting in December.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 4:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 4:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BMYBullishHigh
01

Why it matters

The trial results provide concrete efficacy evidence, likely prompting re‑rating by analysts and short‑term price rally.

02

Market read

First report of pivotal trial data for a major oncology drug; high relevance for biotech investors.

03

What to watch

Potential safety concerns or pricing pressures could temper enthusiasm.

Relevance 7/10Novelty 9/10Timing: ahead of ASH presentation Dec 12‑15

Background

BMS's Zenbexus (iberdomide) is an oral therapy for relapsed/refractory multiple myeloma, recently FDA‑approved based on MRD data.

Company-level read

Ticker impact

$BMYBullishHigh confidence
Context

BMS reported Phase III Zenbexus trial PFS doubled to 42 months, meeting primary endpoints and supporting recent FDA approval.

Expected impact

likely upward pressure as the market incorporates the efficacy data

Evidence & confidence

First disclosure of pivotal trial results for a large‑cap oncology drug; historically such news moves BMY shares.

Market effects

Sector

Strengthens outlook for multiple myeloma therapeutics and may boost related biotech peers.

Regional

Positive for US biotech sector; limited immediate effect on broader markets.

Global

Highlights US pharma innovation; modest global relevance.

Counterpoint

What could challenge this read

If the market has already priced in the data, the upside may be limited.

Key entities

  • Company
    Bristol Myers Squibb

    US‑listed pharmaceutical company (ticker BMY).

  • Drug
    Zenbexus (iberdomide)

    Oral multiple myeloma therapy under BMS.

Read at source← All news

StoryBristol Myers Squibb reports Phase 3 trial shows 51% lower progression risk for Zenbexus in multiple myeloma

Also covered by

3 outlets

Related articles

OCT 8
$BMYMedAI 8/10

Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win - Bristol-Myers Squibb (NYSE:BMY)

Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 trial results for Zenbexus (iberdomide) in multiple myeloma patients. The drug, combined with daratumumab and dexamethasone, showed a 51% reduction in disease progression or death risk, with a median progression-free survival of 42 months. The FDA previously granted accelerated approval for Zenbexus in August. BMY shares were down 1.41% at $58.86 on Thursday.

benzinga.com5 min
OCT 8
$BMYMed

Bristol Myers Squibb Announces ZENBEXUS In Combination With Daratumumab And Dexamethasone Demonstrates Superior Progression-Free Survival Vs. Standard Of Care In Relapsed And Refractory Multiple Myeloma In Phase 3 EXCALIBER-RRMM Study

Bristol Myers Squibb's Phase 3 EXCALIBER-RRMM study showed ZENBEXUS (iberdomide) with daratumumab and dexamethasone improved progression-free survival in relapsed/refractory multiple myeloma vs. standard care. The trial included 800 patients, with 16-month median follow-up. ZENBEXUS has accelerated approval for multiple myeloma treatment.

marketscreener.com2 min
OCT 8
$BMYMedAI 8/10

Bristol Myers Squibb ZENBEXUS cuts progression risk 51%

Bristol Myers Squibb (BMY) reported that its Phase 3 EXCALIBER-RRMM study met its primary endpoint, showing a 51% reduction in disease progression or death risk for relapsed or refractory multiple myeloma patients treated with ZENBEXUS-based therapy. Median progression-free survival was 42 months compared to 20 months with the comparator regimen, with no new safety concerns noted.

grafa.com4 min
OCT 8
$BMYHigh

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combin

Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for ZENBEXUS (iberdomide) with daratumumab and dexamethasone (ZDd) in relapsed/refractory multiple myeloma. ZDd showed a 51% reduction in disease progression or death risk vs. standard treatment (median PFS 42 months vs. 20 months). The safety profile was consistent with prior findings. Results will be presented at the American Society of Hematology meeting.

gurufocus.com2 min